Bio-Rad Laboratories, Inc. filings document operating results, governance, capital structure, and material events for a Delaware company that develops, manufactures, and markets life science research and clinical diagnostics products.
Form 8-K reports furnish quarterly and annual earnings releases, supplemental earnings materials, Regulation FD presentations, Droplet Digital PCR product-portfolio disclosures, and updates related to the company’s investment in Sartorius AG. Proxy materials cover board elections, executive compensation, shareholder voting matters, governance practices, and Class A and Class B common stock disclosures.
BIO-RAD LABORATORIES, INC. (BIO) reported transactions by director Allison Schwartz involving restricted stock units (RSUs) and Class A common stock. On September 4, 2026, she received a grant of 719 RSUs, each representing one share of Class A common stock, vesting over four years. On September 5 and 6, a total of 320 RSUs vested and were converted into an equal number of Class A shares, with 116 shares delivered or withheld to cover the exercise price or tax liability at $386.11 per share. No Rule 10b5-1 trading plan is reported.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (BIO) reported insider equity activity by executive Eva Anette Engelhardt, EVP and President, CDG. On September 4, 2026 she received a grant of 4,313 restricted stock units. On September 5–6, 2026, a total of 2,179 RSUs vested and converted into Class A common shares, with 854 shares delivered or withheld to pay the exercise price or tax liability at $386.11 per share. No Rule 10b5-1 trading plan is reported.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president and general counsel Courtney C. Enloe received and settled equity awards in Bio-Rad Class A common stock. On September 4, 2026, Enloe was granted 2,876 restricted stock units, each representing a contingent right to one Class A share, vesting over four years. On September 5 and 6, 2026, a total of 1,453 restricted stock units vested and were converted into an equal number of Class A shares; 551 shares were delivered or withheld at $386.11 per share for payment of exercise price or tax liability. No Rule 10b5-1 plan is reported.
BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president Rajat Mehta exercised restricted stock units into Bio-Rad Class A common stock and had shares withheld to cover exercise price or tax obligations. On September 5, 2026, he converted RSUs into 456 and 1,370 shares of Class A stock, with 233 and 504 shares, respectively, delivered or withheld at $386.11 per share for exercise price or tax liability. On September 4, 2026, he received a grant of 4,601 restricted stock units that each represent a contingent right to one share of Class A stock and vest over four years.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president James Barry had restricted stock units vest into Bio-Rad Class A common stock on September 1, 2026. A total of 425 shares of Class A common stock were acquired upon RSU vesting, and 154 shares were delivered or withheld to cover the exercise price or tax liability. The RSUs converted included blocks of 174 and 251 units, each representing a right to receive one share of Class A common stock. No transactions are reported as made under a Rule 10b5-1 trading plan.